# Neurosterix funding rounds and investors

As of 13 Nov 2026, Neurosterix has raised $105M across 1 verified round on record, plus 1 round still being checked; latest: $105 million Series B led by RTW Investments, announced 11 Nov 2026.

A clinical-stage biotechnology company focused on transforming neuropsychiatric care through selective allosteric modulation

Website: https://neurosterix.com  
Headquarters: Geneva, Switzerland  
Page: https://fireround.dev/companies/neurosterix

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-11 | Series B | $105 million | RTW Investments | Acorn Bioventures, Affinity Asset Advisors, Dellora Investments, GV (Google Ventures), Ikarian Capital, Janus Henderson Investors, Perceptive Advisors | [globenewswire.com](https://www.globenewswire.com/news-release/2026/11/11/3401151/0/en/addex-spin-out-neurosterix-closes-105-million-series-b-financing.html), [businesswire.com](https://www.businesswire.com/news/home/20261112398888/en/Neurosterix-Announces-%24105-Million-Series-B-Financing-and-Appointments-of-Leading-Neuropsychiatry-Drug-Development-Executives), [biospace.com](https://www.biospace.com/press-releases/addex-spin-out-neurosterix-closes-105-million-series-b-financing) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.